Nasdaq:IBIO
iBio, Inc.
A biotechnology firm leveraging AI-driven discovery platforms to develop novel immunotherapies for cancer treatment.
Key Metrics
Investment Thesis
Bull Case
Investors may view iBio as a high-risk, high-reward opportunity given its proprietary platform and strategic position in the lucrative oncology space. The narrowing losses indicate potential operational maturation that could precede a commercial breakthrough or significant milestone payments from partners. Early entry positions investors in a company with substantial intellectual property assets before potential blockbuster drug approvals.
Bear Case
The stock presents extreme downside risk as the company operates at a significant cash burn rate with no current commercial revenue to support operations. The cumulative retained earnings deficit of -$332.2M signals long-term profitability challenges that require successful capital raising events to avoid insolvency. Without imminent product launches or major licensing deals, the lack of cash reserves poses an existential threat to the business model.
About iBio, Inc.
iBio Inc. is a biotechnology company focused on discovering and developing next-generation therapeutics using its proprietary iBioGen™ platform. The company primarily serves the oncology market with a pipeline of investigational drugs designed to enhance T-cell function for cancer treatment. Key revenue streams currently derive from research collaborations, pre-commercial licensing deals, and milestone payments.
Analysis
Management Discussion
Recent financial performance shows a narrowing net loss from -$65.0M in 2023 to -$18.4M in 2025, suggesting improved operational efficiency or cost management despite low revenue growth. However, the company continues to burn cash at a rate of $15.3M annually with operating expenses exceeding revenue by over $19 million, highlighting an urgent need for successful asset monetization.
Industry Overview
The biotechnology and pharmaceutical industry is characterized by high R&D costs, long development cycles, and regulatory hurdles before products reach market. Companies in this sector often rely on venture capital or public markets for funding until their pipelines generate commercial sales, making valuation highly dependent on pipeline potential rather than current earnings.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $225.0K | $400.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $225.0K | $400.0K |
| Operating Expenses | $29.3M | $16.9M | $19.0M |
| Operating Income | $-29.3M | $-16.6M | $-18.6M |
| R&D | $10.3M | $5.2M | $8.3M |
| G&A | $19.0M | $11.7M | $10.7M |
| Stock-Based Comp | $4.4M | $2.0M | $1.5M |
| Depreciation | $674.0K | $638.0K | $484.0K |
| Amortization | $126.0K | $20.0K | $20.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $32.0K | $1.2M | $225.0K |
| Interest Expense | $83.0K | — | — |
| Interest Income | $213.0K | $363.0K | $437.0K |
| Pre-Tax Income | $-29.3M | $-15.4M | $-18.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-29.3M | $-15.4M | $-18.4M |
| Discontinued Ops | $-35.7M | $-9.5M | $0 |
| Net Income | $-65.0M | $-24.9M | $-18.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-65.0M | $-24.9M | $-18.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $26.3M | $15.7M | $9.7M |
| Cash & Equivalents | $4.3M | $14.2M | $8.6M |
| Inventory | — | $0 | — |
| Prepaid Expenses | $664.0K | $749.0K | $1.0M |
| Other Current Assets | $21.3M | $713.0K | $105.0K |
| Long-Term Assets | $14.9M | $13.1M | $13.5M |
| PP&E (Net) | $4.2M | $3.6M | $3.2M |
| Intangibles | $5.4M | $5.4M | $6.8M |
| Operating Leases | $2.7M | $2.4M | $2.1M |
| Other LT Assets | $2.6M | $1.7M | $1.4M |
| Total Assets | $41.2M | $28.7M | $23.2M |
| Current Liabilities | $21.6M | $3.8M | $6.1M |
| Accounts Payable | $1.8M | $358.0K | $2.2M |
| Current Leases | $389.0K | $436.0K | $490.0K |
| Deferred Revenue | — | $200.0K | $1.2M |
| Other Current Liab | $15.3M | $818.0K | $883.0K |
| Long-Term Liabilities | $4.2M | $3.6M | $2.2M |
| LT Operating Leases | $3.1M | $2.7M | $2.2M |
| Other LT Liab | $1.1M | $882.0K | $0 |
| Total Liabilities | $25.8M | $7.4M | $8.3M |
| Shareholders' Equity | $15.4M | $21.3M | $14.9M |
| Retained Earnings | $-288.9M | $-313.8M | $-332.2M |
| Total L&E | $41.2M | $28.7M | $23.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-65.0M | $-24.9M | $-18.4M |
| Non-Cash Adjustments | $36.2M | $9.9M | $1.7M |
| Working Capital Changes | $-1.6M | $-3.5M | $1.4M |
| Cash from Operations | $-30.4M | $-18.6M | $-15.3M |
| Capital Expenditures | $5.7M | $210.0K | $16.0K |
| Cash from Investing | $7.0M | $906.0K | $742.0K |
| Cash from Financing | $2.3M | $24.5M | $8.9M |
| FX Effect | $33.0K | $0 | $0 |
| Net Change in Cash | $-21.1M | $6.8M | $-5.6M |
| Beginning Cash | $28.7M | $7.6M | $14.4M |
| Ending Cash | $7.6M | $14.4M | $8.8M |
Frequently Asked Questions
How does iBio, Inc. make money?
The company's financial profile suggests a heavy reliance on R&D partnerships and grant funding rather than product sales, with operating expenses dominated by general administration at $10.7M and research and development at $8.3M against negligible revenue of $0.4M in 2025.
What are the main risks for IBIO?
The company faces severe liquidity risks as operating cash flow from activities was -$15.3M and net profit remained at -$18.4M, indicating a heavy reliance on external capital injections. There is substantial dilution risk given the $347.1M in other shareholders' equity and frequent share issuances of $3.5M to fund operations. Regulatory approval timelines for their investigational drugs remain uncertain, creating revenue volatility. The lack of commercial product sales exposes the company to high burn rates without diversified income streams.
What is IBIO's competitive advantage?
The company possesses a proprietary AI-driven discovery platform that accelerates target identification and candidate selection, reducing the traditional time-to-market for new therapies. Its strategic focus on oncology immunotherapies addresses a high-need market with significant unmet medical demand for T-cell enhancing agents.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.